Skip to content
Review Open access

Developing neoantigen cancer vaccines: where are we now?

Sep 2026 · Nature Communications · Vol 17 · 1 citation · 120 references
Medicine

TL;DR

This review examines recent advances in neoantigen cancer vaccine development, highlighting clinical progress across cancer types while discussing ongoing challenges and opportunities to enhance vaccine design, delivery, and combination immunotherapy approaches.

Abstract

The success of immunotherapies such as immune checkpoint blockade and engineered T-cells has demonstrated the immune system’s anticancer potential. Although prophylactic vaccines against oncogenic viruses such as human papillomavirus prevent cancer by blocking infection, therapeutic vaccines targeting tumour-associated or tumour-specific antigens (TAAs/TSAs) have not reliably produced meaningful tumour regressions. Advances in DNA sequencing and computational pipelines for predicting individual, MHC-restricted neoantigens now enable personalized cancer vaccines (PCVs). By targeting neoantigens arising from somatic mutations, PCVs escape the central tolerance that limits anti-TAA vaccines. Multiple clinical trials have shown promise, but PCV design, delivery, and optimal disease settings require further refinement. This review examines recent advances in neoantigen cancer vaccine development, highlighting clinical progress across cancer types while discussing ongoing challenges and opportunities to enhance vaccine design, delivery, and combination immunotherapy approaches.

Read PDF

Similar papers

Review Open access Sep 2026

Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies

Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy, and Artificial Intelligence and Machine Learning are increasingly being incorporated into neoantigen identification pipelines to imp...

D. Mhanna, Bilal Salman, Rawad El Hakim et al. · 0 citations
Review Open access Sep 2026

Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade

By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combinati...

T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al. · 0 citations
Review Sep 2026

Cancer vaccines as targeted therapies: translational advances and challenges.

Current progress in cancer vaccine research is summarized, major translational challenges are discussed, and future directions for the development of effective vaccine-based cancer therapies are considered.

Zahra Shafaghat, Maryam Sadri, Mona Roozbehani et al. · 0 citations
Review Sep 2026

Therapeutic Cancer Vaccines: Classification, Mechanisms, Challenges and Future Perspectives.

BACKGROUND With the rapid advancements in oncology, immunology, and molecular biology, immunotherapy has emerged as a cornerstone of anti-tumor treatment, complementing traditional modalities such as surgery, radiotherapy, and chemotherapy. Therapeutic cancer vaccines are a promising immunotherapy strategy that deliver...

Ju-Wei Gao, Yue Sun, Zi-Jing Han et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.